Past Policy Letters
Back to Congressional Engagement home.



  • SWHR issued a letter to the Office of Human Research Protections (OHRP) on their Federal Policy for the Protection of Human Subjects, or Common Rule. (December 4, 2015)
  • SWHR issued a letter to the National Institute on Drug Abuse (NIDA) on their draft strategic plan. (October 30, 2015)
  • SWHR joined other advocacy groups in asking Chairman Upton and Ranking Member Pallone of the House Committee on Energy and Commerce that Risk Evaluation and Mitigation Strategies (REMS) be used in generic medicines to ensure rigorous safeguards. (April 8, 2015)
  • SWHR issued a letter to the Director of the National Institute of Drug Abuse (NIDA) in support of the NIDA Strategic Plan’s consideration of the impact of sex and gender on drug abuse and addiction. (January 30, 2015)


  • SWHR issued a statement on the findings of a recent report on charity care provided by 340B hospitals, encouraging 340B hospitals to re-examine their charity care practices to ensure that Americans receive the care they need. (March 25, 2014)
  • SWHR signs onto comment letter to Centers for Medicare & Medicaid Services urging them to reconsider their approach and instead work with organizations representing patients, employers and healthcare providers on ways to improve Medicare Advantage and Medicare Part D that build on the strengths of these programs and in the best interests of beneficiaries. (February 18, 2014)
  • SWHR President and CEO signed onto a letter to Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research, urging FDA to reconsider its decision regarding a new treatment for HSDD in women. (January 30, 2014)


  • SWHR President and CEO sent a letter to Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research, urging her to consider scientific evidence for the effectiveness of new treatments for HSDD to improve the quality of life for many women.
  • SWHR signed on to a comment letter to the FDA regarding public availability of data about how new drugs and devices work in women, minorities, and older Americans. (November 20, 2013)
  • SWHR submitted letter to FDA regarding draft guidance proposing to change requirements for demonstrating bioequivalence of generic ophthalmic emulsions, eliminating the need to test these drugs for safety in the human eye. (August 16, 2013)
  • SWHR gave oral comments and submitted written comments to the docket at FDA REMS Standardization and Evaluation Public Meeting at the White Oak campus. (July 25, 2013)
  • SWHR submitted comments and Track and Trace legislation to both House and Senate leadership, the Senate HELP committee and to the House Energy and Commerce committee, among others. (July 23, 2013)